BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)

PHASE3CompletedINTERVENTIONAL
Enrollment

585

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

placebo

Patients receive placebo once daily

DRUG

BIBW 2992

Patients receive afatinib tablets once daily, and can reduce dose for adverse event management. Afatinib is given once daily, continuously until disease progression or unacceptable toxicity.

Trial Locations (90)

Unknown

1200.23.038 Boehringer Ingelheim Investigational Site, Kingman

1200.23.046 Boehringer Ingelheim Investigational Site, Fayetteville

1200.23.027 Boehringer Ingelheim Investigational Site, Anaheim

1200.23.028 Boehringer Ingelheim Investigational Site, Berkeley

1200.23.029 Boehringer Ingelheim Investigational Site, Modesto

1200.23.045 Boehringer Ingelheim Investigational Site, Montebello

1200.23.009 Boehringer Ingelheim Investigational Site, Orange

1200.23.026 Boehringer Ingelheim Investigational Site, Palm Springs

1200.23.024 Boehringer Ingelheim Investigational Site, North Miami Beach

1200.23.020 Boehringer Ingelheim Investigational Site, New York

1200.23.013 Boehringer Ingelheim Investigational Site, Valhalla

1200.23.056 Boehringer Ingelheim Investigational Site, Salt Lake City

1200.23.039 Boehringer Ingelheim Investigational Site, Renton

1200.23.050 Boehringer Ingelheim Investigational Site, Seattle

1200.23.32004 Boehringer Ingelheim Investigational Site, Edegem

1200.23.32003 Boehringer Ingelheim Investigational Site, Ghent

1200.23.32001 Boehringer Ingelheim Investigational Site, Leuven

1200.23.32005 Boehringer Ingelheim Investigational Site, Liège

1200.23.32006 Boehringer Ingelheim Investigational Site, Namur

1200.23.1002 Boehringer Ingelheim Investigational Site, Edmonton

1200.23.1005 Boehringer Ingelheim Investigational Site, Vancouver

1200.23.1009 Boehringer Ingelheim Investigational Site, Toronto

1200.23.1001 Boehringer Ingelheim Investigational Site, Montreal

1200.23.1004 Boehringer Ingelheim Investigational Site, Montreal

1200.23.86001 Boehringer Ingelheim Investigational Site, Beijing

1200.23.86002 Boehringer Ingelheim Investigational Site, Beijing

1200.23.86003 Boehringer Ingelheim Investigational Site, Beijing

1200.23.86009 Boehringer Ingelheim Investigational Site, Chengdu

1200.23.86007 Boehringer Ingelheim Investigational Site, Guangzhou

1200.23.86008 Boehringer Ingelheim Investigational Site, Hangzhou

1200.23.86004 Boehringer Ingelheim Investigational Site, Shanghai

1200.23.86005 Boehringer Ingelheim Investigational Site, Shanghai

1200.23.86006 Boehringer Ingelheim Investigational Site, Shanghai

1200.23.3303A Boehringer Ingelheim Investigational Site, Besançon

1200.23.3303C Boehringer Ingelheim Investigational Site, Besançon

1200.23.3305A Boehringer Ingelheim Investigational Site, Caen

1200.23.3304A Boehringer Ingelheim Investigational Site, La Tronche

1200.23.3304B Boehringer Ingelheim Investigational Site, La Tronche

1200.23.3307A Boehringer Ingelheim Investigational Site, Lyon

1200.23.3301A Boehringer Ingelheim Investigational Site, Paris

1200.23.3302A Boehringer Ingelheim Investigational Site, Paris

1200.23.3302B Boehringer Ingelheim Investigational Site, Paris

1200.23.3306A Boehringer Ingelheim Investigational Site, Toulouse

1200.23.3306C Boehringer Ingelheim Investigational Site, Toulouse

1200.23.49010 Zentralklinik Bad Berka GmbH, Bad Berka

1200.23.49002 Innere Klinik und Poliklinik (Tumorforschung), Essen

1200.23.49003 Asklepios Fachkliniken München-Gauting, Gauting

1200.23.49005 Krankenhaus Großhansdorf, Großhansdorf

1200.23.49008 Universitätsklinik Hamburg-Eppendorf, Hamburg

1200.23.49004 Johannes Gutenberg-Universität Mainz, Mainz

1200.23.49001 Universitätsklinikum Mannheim, Mannheim

1200.23.49006 HSK, Dr. Horst-Schmidt-Kliniken GmbH, Wiesbaden

1200.23.85202 Boehringer Ingelheim Investigational Site, Hong Kong

1200.23.39003 Boehringer Ingelheim Investigational Site, Genova

1200.23.39007 Boehringer Ingelheim Investigational Site, Orbassano (TO)

1200.23.39002 Boehringer Ingelheim Investigational Site, Perugia

1200.23.39004 Boehringer Ingelheim Investigational Site, Prato

1200.23.39008 Boehringer Ingelheim Investigational Site, Roma

1200.23.39001 Boehringer Ingelheim Investigational Site, Rozzano (MI)

1200.23.31002 Boehringer Ingelheim Investigational Site, Amsterdam

1200.23.31001 Boehringer Ingelheim Investigational Site, Groningen

1200.23.31003 Boehringer Ingelheim Investigational Site, Helmond

1200.23.65001 Boehringer Ingelheim Investigational Site, Singapore

1200.23.82005 Boehringer Ingelheim Investigational Site, Gyeonggi-do

1200.23.82006 Boehringer Ingelheim Investigational Site, Hwasun

1200.23.82001 Boehringer Ingelheim Investigational Site, Seoul

1200.23.82002 Boehringer Ingelheim Investigational Site, Seoul

1200.23.82003 Boehringer Ingelheim Investigational Site, Seoul

1200.23.82004 Boehringer Ingelheim Investigational Site, Seoul

1200.23.3405 Boehringer Ingelheim Investigational Site, Barcelona

1200.23.3404 Boehringer Ingelheim Investigational Site, Cruces

1200.23.3401 Boehringer Ingelheim Investigational Site, Madrid

1200.23.3403 Boehringer Ingelheim Investigational Site, Madrid

1200.23.3406 Boehringer Ingelheim Investigational Site, Madrid

1200.23.3402 Boehringer Ingelheim Investigational Site, Valencia

1200.23.88604 Taichung Veterans General Hospital, Taichung

1200.23.88605 China Medical University Hospital, Taichung

1200.23.88606 National Cheng Kung University Hospital, Tainan City

1200.23.88601 National Taiwan University Hospital, Taipei

1200.23.88602 Veterans General Hospital, Taipei

1200.23.88607 Tri-Service General Hospital, Taipei

1200.23.88603 Chang Gung Memorial Hosp-Linkou, Taoyuan District

1200.23.66001 Boehringer Ingelheim Investigational Site, Chiang Mai

1200.23.66003 Boehringer Ingelheim Investigational Site, Pathumwan, Bangkok

1200.23.66002 Boehringer Ingelheim Investigational Site, Songkhla

1200.23.4404 Boehringer Ingelheim Investigational Site, Dundee

1200.23.4403 Boehringer Ingelheim Investigational Site, Edinburgh

1200.23.4401 Boehringer Ingelheim Investigational Site, Glasgow

1200.23.4405 Boehringer Ingelheim Investigational Site, London

1200.23.4406 Boehringer Ingelheim Investigational Site, Sutton

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT00656136 - BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1) | Biotech Hunter | Biotech Hunter